Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy

Phase 2 Unknown 20 enrolled Peking University People's Hospital

RandomizedParallel-groupSingle-blindTreatment

Summary

This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) and cyclosporin a (CSA) on idiopathic inflammatory myopathy (IIM)

Timeline

Start: 2020-01-21
Primary completion: 2021-01-08
Completion: 2021-04-08

Publications

Results Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977 Jul;56(4):255-86. doi: 10.1097/00005792-197707000-00001. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	aldesleukin	Protein / enzyme biologic	1e+06 iu	Subcutaneous
Background	Cyclosporine	Peptide	—	—

Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy

Summary

Timeline

Publications

Drugs

Indications